Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
Chimeric antigen receptor (CAR) T-cell therapy is a novel, customized immunotherapy that is considered a ‘living’ and self-replicating drug to treat cancer, sometimes resulting in a complete cure. CAR T-cells are manufactured through genetic engineering of T-cells by equipping them with CARs to dete...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-11-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2022.2114254 |
_version_ | 1797673137429544960 |
---|---|
author | Tadesse Asmamaw Dejenie Markeshaw Tiruneh G/Medhin Gashaw Dessie Terefe Fitalew Tadele Admasu Wondwossen Wale Tesega Endeshaw Chekol Abebe |
author_facet | Tadesse Asmamaw Dejenie Markeshaw Tiruneh G/Medhin Gashaw Dessie Terefe Fitalew Tadele Admasu Wondwossen Wale Tesega Endeshaw Chekol Abebe |
author_sort | Tadesse Asmamaw Dejenie |
collection | DOAJ |
description | Chimeric antigen receptor (CAR) T-cell therapy is a novel, customized immunotherapy that is considered a ‘living’ and self-replicating drug to treat cancer, sometimes resulting in a complete cure. CAR T-cells are manufactured through genetic engineering of T-cells by equipping them with CARs to detect and target antigen-expressing cancer cells. CAR is designed to have an ectodomain extracellularly, a transmembrane domain spanning the cell membrane, and an endodomain intracellularly. Since its first discovery, the CAR structure has evolved greatly, from the first generation to the fifth generation, to offer new therapeutic alternatives for cancer patients. This treatment has achieved long-term and curative therapeutic efficacy in multiple blood malignancies that nowadays profoundly change the treatment landscape of lymphoma, leukemia, and multiple myeloma. But CART-cell therapy is associated with several hurdles, such as limited therapeutic efficacy, little effect on solid tumors, adverse effects, expensive cost, and feasibility issues, hindering its broader implications. |
first_indexed | 2024-03-11T21:41:04Z |
format | Article |
id | doaj.art-d016dfc731aa4207a65439a5d4cdfa40 |
institution | Directory Open Access Journal |
issn | 2164-5515 2164-554X |
language | English |
last_indexed | 2024-03-11T21:41:04Z |
publishDate | 2022-11-01 |
publisher | Taylor & Francis Group |
record_format | Article |
series | Human Vaccines & Immunotherapeutics |
spelling | doaj.art-d016dfc731aa4207a65439a5d4cdfa402023-09-26T13:19:09ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118610.1080/21645515.2022.21142542114254Current updates on generations, approvals, and clinical trials of CAR T-cell therapyTadesse Asmamaw Dejenie0Markeshaw Tiruneh G/Medhin1Gashaw Dessie Terefe2Fitalew Tadele Admasu3Wondwossen Wale Tesega4Endeshaw Chekol Abebe5University of GondarUniversity of GondarUniversity of GondarCollege of Medicine and Health Science Arbaminch UniversityDebre Tabor UniversityCollege of Medicine and Health Science Arbaminch UniversityChimeric antigen receptor (CAR) T-cell therapy is a novel, customized immunotherapy that is considered a ‘living’ and self-replicating drug to treat cancer, sometimes resulting in a complete cure. CAR T-cells are manufactured through genetic engineering of T-cells by equipping them with CARs to detect and target antigen-expressing cancer cells. CAR is designed to have an ectodomain extracellularly, a transmembrane domain spanning the cell membrane, and an endodomain intracellularly. Since its first discovery, the CAR structure has evolved greatly, from the first generation to the fifth generation, to offer new therapeutic alternatives for cancer patients. This treatment has achieved long-term and curative therapeutic efficacy in multiple blood malignancies that nowadays profoundly change the treatment landscape of lymphoma, leukemia, and multiple myeloma. But CART-cell therapy is associated with several hurdles, such as limited therapeutic efficacy, little effect on solid tumors, adverse effects, expensive cost, and feasibility issues, hindering its broader implications.http://dx.doi.org/10.1080/21645515.2022.2114254carcar t-cell therapystructuregenerationsapprovalclinical trials |
spellingShingle | Tadesse Asmamaw Dejenie Markeshaw Tiruneh G/Medhin Gashaw Dessie Terefe Fitalew Tadele Admasu Wondwossen Wale Tesega Endeshaw Chekol Abebe Current updates on generations, approvals, and clinical trials of CAR T-cell therapy Human Vaccines & Immunotherapeutics car car t-cell therapy structure generations approval clinical trials |
title | Current updates on generations, approvals, and clinical trials of CAR T-cell therapy |
title_full | Current updates on generations, approvals, and clinical trials of CAR T-cell therapy |
title_fullStr | Current updates on generations, approvals, and clinical trials of CAR T-cell therapy |
title_full_unstemmed | Current updates on generations, approvals, and clinical trials of CAR T-cell therapy |
title_short | Current updates on generations, approvals, and clinical trials of CAR T-cell therapy |
title_sort | current updates on generations approvals and clinical trials of car t cell therapy |
topic | car car t-cell therapy structure generations approval clinical trials |
url | http://dx.doi.org/10.1080/21645515.2022.2114254 |
work_keys_str_mv | AT tadesseasmamawdejenie currentupdatesongenerationsapprovalsandclinicaltrialsofcartcelltherapy AT markeshawtirunehgmedhin currentupdatesongenerationsapprovalsandclinicaltrialsofcartcelltherapy AT gashawdessieterefe currentupdatesongenerationsapprovalsandclinicaltrialsofcartcelltherapy AT fitalewtadeleadmasu currentupdatesongenerationsapprovalsandclinicaltrialsofcartcelltherapy AT wondwossenwaletesega currentupdatesongenerationsapprovalsandclinicaltrialsofcartcelltherapy AT endeshawchekolabebe currentupdatesongenerationsapprovalsandclinicaltrialsofcartcelltherapy |